Clinical Implications of Vancomycin Heteroresistant and Intermediately SusceptibleStaphylococcus aureus
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Implications of Vancomycin Heteroresistant and Intermediately SusceptibleStaphylococcus aureus
Authors
Keywords
-
Journal
PHARMACOTHERAPY
Volume 35, Issue 4, Pages 424-432
Publisher
Wiley
Online
2015-04-17
DOI
10.1002/phar.1577
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of Ceftaroline, Vancomycin, Daptomycin, or Ceftaroline plus Daptomycin against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in anIn VitroPharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations
- (2014) Brian J. Werth et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection
- (2013) Anthony M. Casapao et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Novel Combinations of Vancomycin plus Ceftaroline or Oxacillin against Methicillin-Resistant Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA
- (2013) B. J. Werth et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of Ceftaroline Activity against Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate Methicillin-Resistant S. aureus Strains in anIn VitroPharmacokinetic/Pharmacodynamic Model: Exploring the “Seesaw Effect”
- (2013) Brian J. Werth et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activities of Vancomycin, Ceftaroline, and Mupirocin against Staphylococcus aureus Isolates Collected in a 2011 National Surveillance Study in the United States
- (2013) Sandra S. Richter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of Vancomycin in Combination with Piperacillin-Tazobactam or Oxacillin against Clinical Methicillin-Resistant Staphylococcus aureus Isolates and Vancomycin-Intermediate S. aureus IsolatesIn Vitro
- (2013) Thomas J. Dilworth et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of Vancomycin Susceptibility Testing for Methicillin-Resistant Staphylococcus aureus: Comparison of Etest and Three Automated Testing Methods
- (2013) M. J. Rybak et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Evaluation of the Novel Combination of High-Dose Daptomycin plus Trimethoprim-Sulfamethoxazole against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Using anIn VitroPharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations
- (2012) Molly E. Steed et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Vertebral Osteomyelitis Cases Complicated by Bacteremia Treated with High-Dose Daptomycin and Trimethoprim-Sulfamethoxazole
- (2012) Lisa M. Avery et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis
- (2012) S. J. van Hal et al. CLINICAL INFECTIOUS DISEASES
- High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis
- (2012) Jesse T. Jacob et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy
- (2012) T. T. Ho et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Impact of Dose De-Escalation and Escalation on Daptomycin's Pharmacodynamics against Clinical Methicillin-Resistant Staphylococcus aureus Isolates in anIn VitroModel
- (2011) Celine Vidaillac et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroPharmacodynamics of Vancomycin and Cefazolin Alone and in Combination against Methicillin-Resistant Staphylococcus aureus
- (2011) Mao Hagihara et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of Ceftaroline Activity versus Daptomycin (DAP) against DAP-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Strains in anIn VitroPharmacokinetic/Pharmacodynamic Model
- (2011) Molly Steed et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
- (2011) Catherine Liu et al. CLINICAL INFECTIOUS DISEASES
- The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC
- (2011) Hongbin Chen et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA)
- (2011) Steven N. Leonard et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia
- (2011) R. Khatib et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure
- (2011) Peter G. Kelley et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical and Laboratory Characteristics of Invasive Infections Due to Methicillin-Resistant Staphylococcus aureus Isolates Demonstrating a Vancomycin MIC of 2 Micrograms per Milliliter: Lack of Effect of Heteroresistant Vancomycin-Intermediate S. aureus Phenotype
- (2011) S. W. Satola et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Detection of Staphylococcus aureus Isolates with Heterogeneous Intermediate-Level Resistance to Vancomycin in the United States
- (2011) S. S. Richter et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Performance of Various Testing Methodologies for Detection of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus in Bloodstream Isolates
- (2011) S. J. van Hal et al. JOURNAL OF CLINICAL MICROBIOLOGY
- In Vitro Activity of Ceftaroline against Community-Associated Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and Daptomycin-Nonsusceptible Staphylococcus aureus Isolates
- (2010) L. Saravolatz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-IntermediateStaphylococcus aureusIsolates
- (2010) Sebastiaan J. van Hal et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications
- (2010) B. P. Howden et al. CLINICAL MICROBIOLOGY REVIEWS
- Comparison of Detection Methods for Heteroresistant Vancomycin-Intermediate Staphylococcus aureus, with the Population Analysis Profile Method as the Reference Method
- (2010) S. W. Satola et al. JOURNAL OF CLINICAL MICROBIOLOGY
- In Vitro Activity of Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate S. aureus in a Hollow Fiber Model
- (2009) C. Vidaillac et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prospective Comparison of the Clinical Impacts of Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Susceptible MRSA
- (2009) K. C. Horne et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore
- (2009) R. K. C. Fong et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy
- (2009) Fred C. Tenover et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides
- (2009) S. N. Leonard et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Vancomycin MIC plus Heteroresistance and Outcome of Methicillin-Resistant Staphylococcus aureus Bacteremia: Trends over 11 Years
- (2009) A. C. Musta et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Clinical Features of Heteroresistant Vancomycin-IntermediateStaphylococcus aureusBacteremia versus Those of Methicillin-ResistantS. aureusBacteremia
- (2009) Yasmin Maor et al. JOURNAL OF INFECTIOUS DISEASES
- Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
- (2008) M. Rybak et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin
- (2008) T. P. Lodise et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of Inoculum Size and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) on Vancomycin Activity and Emergence of VISA in an In Vitro Pharmacodynamic Model
- (2008) W. E. Rose et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia
- (2008) Benjamin P Howden et al. BMC MICROBIOLOGY
- Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations
- (2008) S. N. Leonard et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Bacteremia and Infective Endocarditis Caused by a Non-Daptomycin-Susceptible, Vancomycin-Intermediate, and Methicillin-Resistant Staphylococcus aureus Strain in Taiwan
- (2008) Y.-T. Huang et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Evaluation of a New Etest Vancomycin-Teicoplanin Strip for Detection of Glycopeptide-Intermediate Staphylococcus aureus (GISA), in Particular, Heterogeneous GISA
- (2008) A. Yusof et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007)
- (2008) M. J. Rybak et al. JOURNAL OF CLINICAL MICROBIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now